Evicenter
P&T meetings

QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Regulatory submission
NDA submitted August 2026
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Microcystic lymphatic malformations

Humanistic burden and health-related quality of life

5 evidence topics · 4 sources